Comparative Pharmacology
Head-to-head clinical analysis: E Z CAT DRY versus E Z PAQUE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: E Z CAT DRY versus E Z PAQUE.
E-Z-CAT DRY vs E-Z-PAQUE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
E-Z-CAT DRY is a barium sulfate suspension used as a radiographic contrast agent. It does not have a pharmacological mechanism of action; it acts by coating the gastrointestinal tract to enhance imaging.
E-Z-PAQUE (barium sulfate) is a radiocontrast agent that attenuates X-rays, providing negative contrast enhancement of the gastrointestinal tract. It works by coating the mucosal surface and filling the lumen, allowing visualization of anatomical structures and pathology.
Oral: 1.5-3.0 mL/kg body weight (maximum 300 mL) of 1.5-2.0% barium sulfate suspension, administered as a single dose for upper GI studies; for CT colonography, 300-500 mL of 1.5-2.0% solution orally 12-24 hours prior to procedure.
Oral or rectal administration: 300-600 mL of a 1% to 2% suspension (10-20 g barium sulfate) for upper GI series; 750-1500 mL of a 15% to 25% suspension (113-375 g barium sulfate) for lower GI series, given as a single dose.
None Documented
None Documented
Terminal elimination half-life: 1–2 hours; clinically, the short half-life allows rapid clearance of contrast agent.
Not applicable; barium sulfate is not systemically absorbed, so no plasma half-life exists. The gastrointestinal transit half-life is approximately 1-2 hours, depending on motility.
Renal: approximately 100% excreted unchanged in urine within 24 hours; biliary/fecal: negligible (<1%).
E-Z-PAQUE (barium sulfate) is not absorbed; elimination is entirely fecal, with 100% of the administered dose excreted unchanged in feces within 24-48 hours. No renal or biliary excretion occurs.
Category C
Category C
Barium Sulfate Contrast Agent
Barium Sulfate Contrast Agent